181 related articles for article (PubMed ID: 14562119)
1. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
Matsuno N; Osato M; Yamashita N; Yanagida M; Nanri T; Fukushima T; Motoji T; Kusumoto S; Towatari M; Suzuki R; Naoe T; Nishii K; Shigesada K; Ohno R; Mitsuya H; Ito Y; Asou N
Leukemia; 2003 Dec; 17(12):2492-9. PubMed ID: 14562119
[TBL] [Abstract][Full Text] [Related]
2. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
Schessl C; Rawat VP; Cusan M; Deshpande A; Kohl TM; Rosten PM; Spiekermann K; Humphries RK; Schnittger S; Kern W; Hiddemann W; Quintanilla-Martinez L; Bohlander SK; Feuring-Buske M; Buske C
J Clin Invest; 2005 Aug; 115(8):2159-68. PubMed ID: 16025155
[TBL] [Abstract][Full Text] [Related]
3. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
4. FLT3-TKD mutation in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
[TBL] [Abstract][Full Text] [Related]
6. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
7. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
[TBL] [Abstract][Full Text] [Related]
8. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
9. New mechanisms of AML1 gene alteration in hematological malignancies.
Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
12. AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication.
Takahashi S; Harigae H; Kameoka J; Sasaki T; Kaku M
Br J Haematol; 2005 Aug; 130(3):428-36. PubMed ID: 16042694
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
[TBL] [Abstract][Full Text] [Related]
15. FLT3 mutations in acute myeloid leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
[TBL] [Abstract][Full Text] [Related]
16. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
17. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
[TBL] [Abstract][Full Text] [Related]
18. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
[TBL] [Abstract][Full Text] [Related]
19. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.
Scholl S; Krause C; Loncarevic IF; Müller R; Kunert C; Wedding U; Sayer HG; Clement JH; Höffken K
J Lab Clin Med; 2005 Jun; 145(6):295-304. PubMed ID: 15976757
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
